Polito C, Oporto M R, Totino S F, La Manna A, Di Toro R
Acta Paediatr Scand. 1986 Mar;75(2):245-50. doi: 10.1111/j.1651-2227.1986.tb10193.x.
Statural growth has been evaluated in 20 prepubertal nephrotic children who received alternate-day prednisone therapy for a year at least. Bone age was assessed in 16 of these children after 1-4 years of therapy. During the follow-up 12 children showed variations in height standard deviation score (SDs) below 0.5, 7 gained more than 0.5 SDs and 1 lost 0.5 SDs. Bone age fell within the normal range for chronological age in all the children studied. On the while alternate-day prednisone therapy does not affect statural growth and bone maturation of children with lipoid nephrosis.
对20名青春期前肾病患儿的身高增长情况进行了评估，这些患儿接受隔日泼尼松治疗至少一年。在治疗1至4年后，对其中16名患儿评估了骨龄。在随访期间，12名患儿的身高标准差评分（SDs）变化低于0.5，7名患儿增加超过0.5个标准差，1名患儿降低了0.5个标准差。在所有研究的患儿中，骨龄均在按年龄计算的正常范围内。总体而言，隔日泼尼松治疗不影响脂性肾病患儿的身高增长和骨骼成熟。
